The FDA has approved a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) elvitegravir, the pharmacokinetic enhancer cobicistat, and the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir disoproxil fumarate (Stribild – Gilead) for treatment of HIV-1 infection in antiretroviral treament-naïve adults. Elvitegravir is the second INSTI to be approved by the FDA for use in HIV treatment; raltegravir (Isentress) was the first.1

FIRST-LINE TREATMENT OF HIV — Antiretroviral treatment regimens usually include a "backbone" and a "base". Recommended choices for first-line therapy of HIV infection, depending on the results of resistance testing, include a non-nucleoside reverse transcriptase inhibitor (NNRTI) such as efavirenz, a ritonavir-boosted protease inhibitor such as atazanavir, or an INSTI as the base, ... more      

Would you like to read the rest of this article?  Gain access below.